MedTrace Logo

Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients

NCT00393861 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2016-03-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effectiveness of oxaliplatin and bevacizumab in patients with refractory or relapsed germ cell tumors.

Conditions

  • Neoplasms, Germ Cell and Embryonal

Interventions

DRUG

Bevacizumab and Oxaliplatin

Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Indiana University

    lead OTHER

Principal Investigators

  • Lawrence Einhorn, MD · Indiana Univeristy School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2012-10-31
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00393861 on ClinicalTrials.gov